產(chǎn)品名稱：ANA Hep Screen ELISA 產(chǎn) 地：Demeditec 產(chǎn)品貨號(hào)：DE7020 產(chǎn)品規(guī)格：96 Tests 產(chǎn)品說明： Special remarks: The ANA Hep Screen assay is a qualitative enzyme immunoassay (EIA) intended to screen for the presence of antinuclear antibodies (ANAs) in human serum or plasma as an aid in the diagnosis of certain systemic rheumatic diseases. This assay collectively detects, in one well, ANAs against double stranded DNA (dsDNA, nDNA), histones, SS-A/Ro, SS-B/La, Sm, SmRNP, Scl-70, PM-Scl-100, Jo-1, and centromeric antigens. Inflammatory connective tissue diseases are characterized by idiopathic genesis along with disturbances in terms of cellular and humoral immunity, systemic organ failure and a chronic course of disease. Additionally, connective tissue diseases exhibit overlapping symptomatic features that render an accurate diagnosis difficult. Considering the diversity of mixed connective tissue diseases, such disorders exhibit a common serological characteristic; the presence of anti-nuclear antibodies. These antibodies are directed against parts of the cell nucleus and the cytoplasm, and many rheumatic diseases are characterized by the presence of one or more of these ANAs. Antibodies to double-stranded DNA (dsDNA), single-stranded DNA (ssDNA), histone, nuclear ribonucleoprotein (RNP) and Smith antigen (Sm) are associated with SLE, while antibodies to Sjogren´s Syndrome A (SSA/Ro) and Sjogren´s Syndrome B (SSB/La) can occur in both SLE and Sjogren´s Syndrome (SS). Antibodies to Jo-1 may be observed in polymyositis and dermatomyositis, while antibodies to scleroderma-associated antigen (Scl-70) and centromere can occur in patients with progressive systemic sclerosis (PSS). Anti-histone antibodies are associated with SLE and drug-induced lupus, while anti-RNP antibodies are linked with mixed connective tissue disease (MCTD) and with SLE. Antibodies directed against centromere are associated with CREST syndrome. Although IFA technology was traditionally used to detect autoantibodies in conjunction with HEp2 cells, it is now widely acknowledged that ELISA technology offers an excellent alternative. IFA technology is subject to errors of interpretation and can be labor-intensive when applied to a large number of unknown samples. The ANA Hep Screen ELISA assay allows for collective and simultaneous screening for the autoantibodies of major significance in one microwell, and effectively eliminates the need for individual interpretation that is inherent in IFA technology. 上海玉博生物技術(shù)有限公司在為生命科學(xué)領(lǐng)域提供豐富的產(chǎn)品與信息資源方面處于國內(nèi)**地位，公司提供的產(chǎn)品涵蓋了二十多個(gè)國家近五十萬種產(chǎn)品，而且產(chǎn)品的數(shù)量與信息在不斷的增長和更新，公司提供的產(chǎn)品能夠使生命科學(xué)工作者加快對(duì)生物化學(xué)，分子生物學(xué)，細(xì)胞生物學(xué)以及蛋白質(zhì)組學(xué)研究的認(rèn)知，以及分子診斷和臨床醫(yī)學(xué)領(lǐng)域的應(yīng)用。
滬公網(wǎng)安備 31011002002623號(hào)
